All In Biotech

Drug Trial Radar · NCT06824181

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

580

Actual

Start

Feb 27, 2025

Primary completion

Sep 10, 2027

Study completion Sep 10, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age (MoA). Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.

Conditions

  • Pneumococcal Immunization

Interventions

  • PCV21 vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • Prevnar 20 vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • M-M-R II vaccineBiological

    Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular

  • RotarixBiological

    Pharmaceutical form:Solution-Route of administration:Oral

  • RotaTeqBiological

    Pharmaceutical form:Solution-Route of administration:Oral

  • Vaxelis vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • VarivaxBiological

    Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular

  • PriorixBiological

    Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous

  • VAQTABiological

    Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular

  • HavrixBiological

    Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of any immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
  2. Presence of solicited injection site and systemic reactions through 7 days after each vaccine injectionTime frame: Through 7 days after each vaccine injection
  3. Presence of unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs through 30 days after each vaccine injectionTime frame: Through 30 days after each vaccine injection
  4. Presence of serious adverse events (SAEs) throughout the study (through 6 months post- last vaccine injection)Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months
  5. Presence adverse events of special interest (AESIs) throughout the study (through 6 months post- last vaccine injection)Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months
  6. Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days PD4Time frame: 30 days PD4

Locations

27 sites in 4 countries. Site status is shown where the registry gives one.

  • Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400025

    Los Angeles, California

  • The Medici Medical Research- Site Number : 8400008

    Hollywood, Florida

  • Clinsearch Inc at Dr. Gala, LLC- Site Number : 8400027

    Miami, Florida

  • Atlantis Clinical Research- Site Number : 8400009

    Miami, Florida

  • Velocity Clinical Research - Sioux City- Site Number : 8400007

    Sioux City, Iowa

  • Private Practice - Dr. Michael W. Simon- Site Number : 8400001

    Lexington, Kentucky

  • Velocity Clinical Research - New Orleans- Site Number : 8400006

    New Orleans, Louisiana

  • Finger Lakes Medical Research - Cortland- Site Number : 8400022

    Cortland, New York

  • University of Rochester Medical Center- Site Number : 8400019

    Rochester, New York

  • SUNY Upstate Medical University - Syracuse- Site Number : 8400015

    Syracuse, New York

  • Kid's Way Pediatrics- Site Number : 8400013

    Hermitage, Pennsylvania

  • Carolina Family Care - Charleston- Site Number : 8400014

    Charleston, South Carolina

  • Helios Clinical Research - BUR PEDI- Site Number : 8400016

    Burleson, Texas

  • Clinsearch Inc at VAST Clinical Research- Site Number : 8400028

    Euless, Texas

  • DM Clinical Research - Houston - Jones Road- Site Number : 8400012

    Houston, Texas

  • University of Texas Medical Branch at Galveston- Site Number : 8400005

    League City, Texas

  • Javara - Privia Medical Group North Texas - Stephenville- Site Number : 8400024

    Stephenville, Texas

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 4840003

    León, Guanajuato, Mexico

  • Investigational Site Number : 4840001

    Mexico City, Mexico City, Mexico

  • Investigational Site Number : 4840002

    Temixco, Morelos, Mexico

  • Investigational Site Number : 4840004

    Tlaltizapán, Morelos, Mexico

  • Investigational Site Number : 6080001

    Cebu City, Philippines

  • Investigational Site Number : 6080002

    Quezon City, Philippines

  • Investigational Site Number : 6080003

    Quezon City, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.